

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Phospho-TIF1-beta (Ser824) Antibody

RRID:AB_2209906

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4127, RRID:AB_2209906

Antibody Information

URL: http://antibodyregistry.org/AB_2209906

Proper Citation: Cell Signaling Technology Cat# 4127, RRID:AB_2209906

Target Antigen: TRIM28

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W

Antibody Name: Phospho-TIF1-beta (Ser824) Antibody

Description: This polyclonal targets TRIM28

Target Organism: human

Antibody ID: AB_2209906

Vendor: Cell Signaling Technology

Catalog Number: 4127

Record Creation Time: 20250820T065532+0000

Record Last Update: 20250821T011323+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-TIF1-beta (Ser824) Antibody.

No alerts have been found for Phospho-TIF1-beta (Ser824) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Han Y, et al. (2024) gp78-regulated KAP1 phosphorylation induces radioresistance in breast cancer by facilitating PPP1CC/PPP2CA ubiquitination. *iScience*, 27(9), 110847.

Nair JR, et al. (2024) Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer. *iScience*, 27(12), 111283.

Huang M, et al. (2023) FACS-based genome-wide CRISPR screens define key regulators of DNA damage signaling pathways. *Molecular cell*, 83(15), 2810.

Sahgal P, et al. (2023) Replicative stress in gastroesophageal cancer is associated with chromosomal instability and sensitivity to DNA damage response inhibitors. *iScience*, 26(11), 108169.

Egger T, et al. (2022) A clinically relevant heterozygous ATR mutation sensitizes colorectal cancer cells to replication stress. *Scientific reports*, 12(1), 5422.

Ka NL, et al. (2021) IFI16 inhibits DNA repair that potentiates type-I interferon-induced antitumor effects in triple negative breast cancer. *Cell reports*, 37(12), 110138.